The HARMONY Alliance will present new results of Big Data Research Projects at the 63nd Annual Meeting of the American Society of Hematology (ASH), taking place as a hybrid meeting on December 11–14, 2021.
In addition, representatives of ASH and HARMONY will participate in an inspiring dedicated session about the role of Real-World data collection in Hematologic Malignancies.
New HARMONY results in AML and CLL
At ASH 2021, HARMONY researchers will present new results related to Acute Myeloid Leukemia (AML) and to Chronic Lymphocytic Leukemia (CLL). Using data from thousands of patients with CLL, they have produced new insights that may be used to identify patients with an unfavorable prognosis. This may result in better-informed treatment choices in the future.
- Does RAD21 co-mutation have a role in DNMT3A mutated AML? Results of the HARMONY Alliance database - Raul Azibeiro, University of Salamanca, Spain
- Harmony Alliance provides a machine learning researching tool to predict the risk of relapse after first remission in AML patients treated without allogeneic hematopoietic stem cell transplantation (alloHSCT) - Marta Sobas, Medical University of Wroclaw, Poland
- Impact of Gender on Molecular AML Subclasses – a HARMONY Alliance Study - Tommaso Matteuzzi, Alma Mater Studiorum - Università di Bologna, Italy
- Clinical impact of recurrent gene mutations in chronic lymphocytic leukemia: a retrospective, multi-center cohort study by ERIC, the European Research Initiative on CLL, in Harmony - Larry Mansouri, ERIC European Research Initiative on CLL/Karolinska Institutet, Sweden
Dedicated ASH-HARMONY session
This joint session about the role of Real-World data collection in Hematologic Malignancies will take place on December 12, 2021 4:30-6:00PM EST (Georgia World Congress Center, B312-B314) and will address:
- Challenges, & Potential Solutions to Accelerate Research
- Regulatory Perspective on Data sharing and RWD to generate RWE
- Patients Viewpoint on Real World Data Sharing
- Clinical Viewpoints on Real World Data for Research
- Martin S. Tallman, MD; Memorial Sloan-Kettering Cancer Center New York, USA - The Role of Real-World Data in Hematologic Malignancy Research (ASH)
- John Gribben, MD, DSc, FRCP, FRCPath, FMedSci; Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, United Kingdom - Role of Real-World Data in Hematologic Malignancy Research (HARMONY)
- William A. Wood, MD,MPH; University of North Carolina, USA - Real-World Data Expectations, Challenges, and Potential Solutions to Accelerate Research (ASH Research Collaborative)
- Guillermo Sanz, MD,PhD; Hospital Universitario La Fe de la Comunidad Valenciana, Spain - Real-World Data Expectations, Challenges, and Potential Solutions to Accelerate Research (HARMONY)
- Nicole J. Gormley, MD; U.S. Food and Drug Administration, USA - Regulatory Perspective on Data sharing and Real-World Data to Generate Real-World Evidence
- Jan Geissler, Leukanet / representing the HARMONY Alliance Patient Cluster, Germany - Patient's Viewpoint on Real World Data Sharing (HARMONY)
- Kenneth C. Anderson, MD; Dana-farber/Boston Children's Cancer and Blood Disorders Center, USA - Multiple Myeloma Real World Data for Research (ASH Research Collaborative)
- Mario Boccadoro, Universita degli studi di Torino, Italy - Multiple Myeloma Real-World Data for Research (HARMONY)
- Laura C. Michaelis, MD; The Medical College of Wisconsin, USA - Acute Myeloid Leukemia Real World Data for Research (ASH Research Collaborative)
- Lars Bullinger; Charite University Berlin, Germany - Acute Myeloid Leukemia Real World Data for Research (HARMONY)
- Jesus Maria Hernández-Rivas, MD PhD; IBSAL, Spain - Conclusion: Going beyond scientific collaboration to facilitate the access to the right treatment for the right hematology patient at the right time (HARMONY).
ASH 2021: Participants will be able to join the meeting either in person at the Georgia World Congress Center in Atlanta, Georgia or virtually. The ASH Annual Meetings provide a unique opportunity for hematology professionals to exchange knowledge and expertise on a wide range of topics, hear the latest scientific discoveries in the field of hematology, and explore strategies to improve clinical practice and patient outcomes. Click here to visit the official ASH congress website >
ASH2020: Read about the HARMONY Alliance participation in the previous edition of the ASH Annual Meeting >
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on various Hematologic Malignancies. The HARMONY Alliance, funded by Innovative Medicines Initiative, unites more than 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. The aim is to accelerate the development of more effective treatments. Data are stored in HARMONY’s Big Data Platform, which has already identified over 80,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!